News for Healthier Living

Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies

A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies--including ovarian and uterine cancers--found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

April 20, 2026


May 1 2026

April 30 2026

April 29 2026

April 28 2026

April 27 2026

April 26 2026

April 25 2026

April 24 2026

April 23 2026

April 22 2026

April 21 2026

April 20 2026

April 19 2026

April 18 2026